HC Wainwright reaffirmed their buy rating on shares of Werewolf Therapeutics (NASDAQ:HOWL) in a research report report published on Tuesday morning, PriceTargets.com reports. HC Wainwright currently has a $32.00 price target on the stock.
Several other analysts have also recently commented on the stock. Jefferies Financial Group began coverage on shares of Werewolf Therapeutics in a report on Tuesday, May 25th. They set a buy rating and a $22.00 price target for the company. Bank of America began coverage on shares of Werewolf Therapeutics in a report on Friday, September 10th. They....More>>>